SynthesisMolecular biology reports2011
IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls.
Synthesis in Molecular biology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 11 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer.Oncotarget · 2017Pooled it
- Pooled it
- Association of p21 3' UTR gene polymorphism with cancer risk: Evidence from a meta-analysis.Scientific reports · 2015Pooled it
- Lack of association between a functional polymorphism (rs1800796) in the interleukin-6 gene promoter and lung cancer.Diagnostic pathology · 2014Pooled it
- Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.Human genomics · 2013Pooled it
- Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk.Molecular biology reports · 2013Pooled it
- IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review.Molecular biology reports · 2012Pooled it
- DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case-control studies.Molecular biology reports · 2012Pooled it
- Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls.Molecular biology reports · 2011Pooled it
- Pooled it
- Single nucleotide polymorphism of transforming growth factor-β1 and interleukin-6 as risk factors for ovarian cancer.Central-European journal of immunology · 2020Article
- DNMT3B -579 G>T Promoter Polymorphism and the Risk of Gastric Cancer in the West of Iran.Journal of gastrointestinal cancer · 2018Article
- Serum Interleukin-6 Level and the rs1800795 Polymorphism in its Gene Associated with Neuroblastoma Risk in Chinese Children.Chinese medical journal · 2018Article
- Association between the rs1800795G>C polymorphism in the promoter of interleukin-6 gene and bladder cancer.International journal of clinical and experimental pathology · 2018Article
- Relationships between Common and Novel Interleukin-6 Gene Polymorphisms and Risk of Cervical Cancer: a Case-Control Study.Pathology oncology research : POR · 2017Article
- Association between IL-6 Gene (-174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk.Pathology oncology research : POR · 2016Article
- Longitudinal Study of DNA Methylation of Inflammatory Genes and Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- Association of interleukin-6 genetic polymorphisms with risk of OSCC in Indian population.Meta gene · 2015Article
- Ethnic variation in interleukin-6 -174 (g/c) polymorphism in the malaysian population.Balkan journal of medical genetics : BJMG · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine involved in different physiologic and pathophysiologic processes and plays important roles in the etiology of cancer. The -174G>C polymorphism of the IL-6 gene influences IL-6 transcription and has been implicated in cancer risk. However, published data have been conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 29,377 cancer cases and 37,739 controls from 50 published case-control studies was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between -174G>C polymorphism and cancer risk. Overall meta-analysis indicated that no association was found between -174G>C genotypes and cancer risk. However, the positive association was found in bladder cancer (OR=4.33, 95% CI: 1.93-9.71 for CC vs. GC, OR=2.81, 95% CI: 1.39-5.68 for CC vs. GG, and OR=2.19, 95% CI: 1.32-3.64 for CC vs. GG/GC), and among Asians (OR=2.08, 95% CI: 1.07-4.06 for CC vs. GG, and OR=2.20, 95% CI: 1.02-4.74 for CC vs. GG/GC) and Africans (OR=1.61, 95% CI: 1.07-2.42 for GC vs. GG). This meta-analysis showed the evidence that the -174G>C of the IL-6 gene was a low-penetrance susceptibility gene for bladder cancer. Further larger, preferably prospective studies are needed to confirm this relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.